🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

J. B. Chemicals & Pharmaceuticals Limited JBCHEPHARM NIFTY_SMALLNSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.jbpharma.com
Company Profile ↓
₹2,465.10
+54.96% 1Y
Mkt Cap₹39,579.33 Cr
P/E59.31
P/B9.50
Div. Yield0.76%
52W High₹2,487.60
52W Low₹1,585.06
Book Value₹259.05
EPS (TTM)₹41.56

Company Overview

J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company's API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; and nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dosage forms, such as tablets, capsules, liquids, gels, lozenges, creams, injectables, powder, cold rubs, eye drops, and troches; and soft-centered, powder, medicated, and herbal lozenges, as well as various pharmaceutical dosage forms. In addition, the company offers a range of contrast media products, including x-ray, magnetic resonance imaging (MRI), and ultrasound scanners; and contract manufacturing services. It provides its products to gastroenterology, anti-infectives, wound care, neonatology and pediatrics, genecology, dental, vitamins and minerals, hypertension, diabetes, nephrology, respiratory, pain-analgesic, dermatology, antivirals, lozenges, and contrast media and radio diagnostic therapeutic areas. J. B. Chemicals & Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Mumbai, India.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 17.1%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 21.9%.

Consistent Profit Growth

Net profit has compounded at 20.1% per year over the last five years.

Healthy Margins

Maintains a net profit margin of 17.4%.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.09.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹4,076.20 Cr (+5.5% YoY); net profit ₹709.47 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +5.5%, earnings +7.6%.
  • 5-Year Trend Long-term compounding — revenue CAGR 9.4%, profit CAGR 20.1%.

Growth & Price Performance

Compounded Sales Growth

5 Years:9.36%
1 Year:5.55%

Compounded Profit Growth

5 Years:20.07%
1 Year:7.56%

Stock Price Performance

1 Year:+54.96%
6 Months:+33.06%
3 Months:+23.90%
1 Month:+12.42%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 98% of range
₹1,585.06 ₹2,487.60
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)76.35 · Overbought
Price Performance
1M+12.42%
3M+23.90%
6M+33.06%
1Y+54.96%
Valuation vs Sector

P/E of 59.31 is above the sector median of 39.97 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Healthy ROCE of 21.9%.
  • Profit CAGR of 20.1% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading at a high P/E of 59.3.
  • RSI at 76 suggests overbought conditions.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
59.31
Industry PE
39.97
Forward P/E
33.83
PEG Ratio
-
Book Value
₹259.05
Price to Book
9.50
P/S
9.52
EV/EBITDA
35.10
Dividend Yield
0.76%

Growth (CAGR)

Revenue 5Y
9.36%
Profit 5Y
20.07%
Revenue (YoY)
5.55%
Earnings (YoY)
7.56%

Profitability & Returns

ROCE
21.88%
ROE
17.06%
ROA
14.28%
Profit Margin
17.41%
Op Margin
22.10%
Gross Margin
67.51%
EPS (Latest Qtr)
₹6.32
EPS (TTM)
₹41.56

Balance Sheet & Liquidity

Debt/Equity
0.09
Quick Ratio
3.77
Current Ratio
4.92
Debt
₹3.59 Cr
Total Assets
₹4,968.65 Cr
Current Assets
₹2,909.37 Cr
Working Capital
₹2,318.21 Cr

Ownership

Promoter Holding
49.23%
Chg in Prom Hold
-0.00%
FII / Inst Holding
30.78%
Chg in FII Hold
0.08%

Financial Snapshot

Enterprise Value
₹39,579.33 Cr
Total Revenue (TTM)
₹4,076.20 Cr
EBITDA
₹1,140.28 Cr
Free Cash Flow
₹620.73 Cr
Operating Cash Flow
₹703.92 Cr
Shares Outstanding
₹16.06 Cr
Gross Margin
67.51%
Payout Ratio
44.32%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 JBCHEPHARM J. B. Chemicals & Pharmaceuticals Limited NIFTY_SMALLNSEPHARMA 2,465.10 59.31 ₹39,579.33 Cr 0.76% 21.88% 17.06% 9.36% 20.07%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 762.00 Cr896.00 Cr882.00 Cr845.00 Cr862.00 Cr1,004.00 Cr1,001.00 Cr963.00 Cr949.48 Cr1,093.94 Cr1,084.90 Cr1,064.72 Cr904.23 Cr
Cost of Revenue --------321.64 Cr347.10 Cr345.49 Cr329.43 Cr274.25 Cr
Gross Profit --------627.84 Cr746.84 Cr739.41 Cr735.29 Cr629.98 Cr
Operating Expenses 599.00 Cr664.00 Cr638.00 Cr621.00 Cr664.00 Cr724.00 Cr730.00 Cr709.00 Cr447.84 Cr488.67 Cr474.25 Cr484.82 Cr478.86 Cr
Operating Income 132.00 Cr201.00 Cr212.00 Cr189.00 Cr157.00 Cr239.00 Cr229.00 Cr213.00 Cr180.00 Cr258.17 Cr265.16 Cr250.47 Cr151.12 Cr
EBITDA 164.00 Cr232.00 Cr244.00 Cr223.00 Cr198.00 Cr280.00 Cr271.00 Cr255.00 Cr240.92 Cr315.42 Cr324.94 Cr314.10 Cr185.93 Cr
Interest Expense 14.00 Cr12.00 Cr10.00 Cr12.00 Cr9.00 Cr6.00 Cr2.00 Cr3.00 Cr1.45 Cr1.11 Cr1.35 Cr1.88 Cr1.23 Cr
Pretax Income 122.00 Cr194.00 Cr209.00 Cr184.00 Cr165.00 Cr240.00 Cr237.00 Cr218.00 Cr193.03 Cr271.61 Cr279.15 Cr266.87 Cr134.69 Cr
Tax Provision 34.16 Cr52.38 Cr58.52 Cr49.68 Cr37.95 Cr62.40 Cr61.62 Cr54.50 Cr47.34 Cr69.23 Cr71.33 Cr68.98 Cr33.32 Cr
Net Income 88.00 Cr142.00 Cr151.00 Cr134.00 Cr126.00 Cr177.00 Cr175.00 Cr162.00 Cr145.69 Cr202.38 Cr207.82 Cr197.89 Cr101.37 Cr
Diluted EPS 5.669.199.728.618.1311.3911.2410.459.1712.7513.0812.456.32

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 1,144.00 Cr1,210.00 Cr1,344.00 Cr1,408.00 Cr1,643.00 Cr1,775.00 Cr2,043.00 Cr-3,116.51 Cr3,447.67 Cr3,862.04 Cr4,076.20 Cr
Cost of Revenue --------1,184.80 Cr1,202.95 Cr1,340.32 Cr1,324.30 Cr
Gross Profit --------1,931.71 Cr2,244.72 Cr2,521.73 Cr2,751.89 Cr
Operating Expenses 964.00 Cr1,004.00 Cr1,112.00 Cr1,191.00 Cr1,337.00 Cr1,397.00 Cr1,482.00 Cr-1,344.22 Cr1,492.09 Cr1,667.21 Cr1,851.02 Cr
Operating Income 141.00 Cr165.00 Cr185.00 Cr161.00 Cr250.00 Cr312.00 Cr491.00 Cr-587.49 Cr752.63 Cr854.52 Cr900.88 Cr
EBITDA 180.00 Cr206.00 Cr232.00 Cr218.00 Cr306.00 Cr378.00 Cr560.00 Cr-705.05 Cr933.48 Cr1,069.12 Cr1,140.28 Cr
Interest Expense 7.00 Cr11.00 Cr5.00 Cr3.00 Cr5.00 Cr3.00 Cr7.00 Cr-35.41 Cr43.65 Cr10.69 Cr5.44 Cr
Pretax Income 146.00 Cr212.00 Cr230.00 Cr194.00 Cr287.00 Cr349.00 Cr597.00 Cr-555.23 Cr751.51 Cr887.39 Cr952.34 Cr
Tax Provision 45.26 Cr48.76 Cr46.00 Cr54.32 Cr91.84 Cr76.78 Cr149.25 Cr-145.23 Cr198.88 Cr227.81 Cr242.86 Cr
Net Income 100.00 Cr163.00 Cr184.00 Cr139.00 Cr194.00 Cr272.00 Cr449.00 Cr-409.84 Cr552.63 Cr659.58 Cr709.47 Cr
Diluted EPS 5.929.5810.858.2812.0517.6028.9824.9126.1734.8541.56-

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 1,487.00 Cr1,648.00 Cr1,674.00 Cr1,765.00 Cr1,792.00 Cr1,814.00 Cr2,231.00 Cr-3,553.87 Cr3,994.13 Cr4,273.78 Cr4,968.65 Cr
Current Assets --------1,528.03 Cr1,853.35 Cr1,922.74 Cr2,909.37 Cr
Cash & Equivalents --------76.93 Cr88.22 Cr115.09 Cr110.18 Cr
Inventory --------430.48 Cr502.51 Cr528.96 Cr683.40 Cr
Receivables --------575.80 Cr686.92 Cr815.38 Cr780.91 Cr
Total Liabilities --------1,073.52 Cr1,070.80 Cr840.46 Cr809.43 Cr
Current Liabilities --------554.45 Cr868.23 Cr632.34 Cr591.16 Cr
Long Term Debt --------383.22 Cr23.64 Cr0-
Total Debt 127.00 Cr193.00 Cr49.00 Cr29.00 Cr26.00 Cr29.00 Cr45.00 Cr-572.45 Cr377.66 Cr27.89 Cr3.59 Cr
Total Equity 995.00 Cr1,184.00 Cr1,364.00 Cr1,442.00 Cr1,480.00 Cr1,435.00 Cr1,809.00 Cr-2,480.35 Cr2,923.33 Cr3,433.32 Cr4,159.22 Cr
Shares Outstanding --------15.48 Cr15.52 Cr15.57 Cr16.06 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 127.00 Cr140.00 Cr201.00 Cr123.00 Cr194.00 Cr276.00 Cr315.00 Cr-625.61 Cr800.61 Cr902.45 Cr703.92 Cr
Investing Cash Flow -112.00 Cr-26.00 Cr-45.00 Cr-21.00 Cr-28.00 Cr24.00 Cr-231.00 Cr--961.79 Cr-403.83 Cr-295.90 Cr-585.88 Cr
Financing Cash Flow -1.00 Cr-100.00 Cr-184.00 Cr-60.00 Cr-156.00 Cr-306.00 Cr-87.00 Cr-356.54 Cr-385.49 Cr-579.67 Cr-123.10 Cr
Capital Expenditure -71.00 Cr-203.00 Cr-153.00 Cr-29.00 Cr-41.00 Cr-71.00 Cr0--764.95 Cr-261.37 Cr-120.31 Cr-83.19 Cr
Free Cash Flow 56.00 Cr-63.00 Cr48.00 Cr94.00 Cr153.00 Cr205.00 Cr315.00 Cr--139.33 Cr539.24 Cr782.14 Cr620.73 Cr
Net Change in Cash 13.00 Cr15.00 Cr-28.00 Cr43.00 Cr11.00 Cr-6.00 Cr-3.00 Cr-20.36 Cr11.30 Cr26.88 Cr-5.05 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------62.0%65.1%65.3%67.5%
Operating Margin % 12.3%13.6%13.8%11.4%15.2%17.6%24.0%-18.9%21.8%22.1%22.1%
Net Margin % 8.7%13.5%13.7%9.9%11.8%15.3%22.0%-13.2%16.0%17.1%17.4%
ROE % 10.1%13.8%13.5%9.6%13.1%19.0%24.8%-16.5%18.9%19.2%17.1%
ROCE % --------19.6%24.1%23.5%20.6%

Shareholding Pattern

Insiders
49.23%
Institutions
30.78%
Public Float
60.62%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for JBCHEPHARM

Google News hu, 25 Jun 2026

JBCHEPHARM Forecast — Price Target — Prediction for 2027 - TradingView

<a href="https://news.google.com/rss/articles/CBMifkFVX3lxTFB1SldUTkN2OEJNVm5YMGtIN0g5OGl4XzM4ZE9LRXZ6U2xZSVZrRlFoQTJDZTZhdHlYU0tCLTAtRDZSNU03dndpeWR4OWtsdi1Ja0xncU1LV2l1cFdLdlZMMkZPQ0FLRGlYYWJ6dG40czc2SzBKOFNmZVU3VkRGZw?oc=5" target="_blan…

Google News ue, 11 Nov 2025

J. B. Chemicals & Pharmaceuticals Limited's (NSE:JBCHEPHARM) Stock Is Going Strong: Is the Market Following Fundamentals? - simplywall.st

<a href="https://news.google.com/rss/articles/CBMihgJBVV95cUxPM2VTZ1RVX3JXVXBtME5FWUVHQ21XUXExdlZhckhuVno5d0NvakRia0N6TXFCc1dBdm5na2hQRFdOd0hkYzFfUkFOZzUxNFNjeUVpNzhDMnhqZXJ3X2VySFRvdlJtVjF2OHo2WHU0M0ViMzVIRkt2S2pRVUg0ajBhd3E2YUU4ZmtXeDNtaU…

Google News Wed, 08 Jul 2026

Pharma Stocks Outshine PSU & Energy Stocks on BSE, NSE - HDFC Sky

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxOVjJmTFZQWGVsY3B0ZldtWjhMYTZMWjhwNjR6bDBncW9QRHNlSWNkZjhLam11cWdZTXNaOE1ENTI4NXltMFhvZmIydEUzWHNkOHhCZ241OGtCOVFaa2NodDRET3RYcGR3Z0dEX3UyRHF5aWFqNU5QZzJ3RDlMUUg3ZFp4bTdrVDMwT1l4WU…

Google News Mon, 25 May 2026

There's A Lot To Like About J. B. Chemicals & Pharmaceuticals' (NSE:JBCHEPHARM) Upcoming ₹9.30 Dividend - simplywall.st

<a href="https://news.google.com/rss/articles/CBMihgJBVV95cUxQaElnYUxDUWY0dnlyUi1SRzRVWWVYM05pckFBQ0diSGRsWmVkUm1MbUp3Z29oZHU4Vnc3NHdac2JoN3JfVFJqWlUtN291ci1rT1dEbWhleDJycE80cllmUXhWdUp4Y3dBelVrRVBXTzFiVTVINEV0WHkyRk5YUmhWalo4OGlVZUpPZGQwaV…

Google News Fri, 14 Nov 2025

J. B. Chemicals & Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models - simplywall.st

<a href="https://news.google.com/rss/articles/CBMihgJBVV95cUxOQmtxQ3R0OWhnMUl6T0JWdU56U0IzWW9PY0JtVklmMExwYV9oR1JDblZYNkxHY1RSRExvZklUOV95SGJPcXRrRmxsRVgzclc2WTJVemFVWGFBNTk5QWNFckJyVEhBWjBocE0xT0w4a19pVXNUN1paNExSVlpLbTNxenltM20zZjlrdWFYdV…

Google News Sun, 25 Jun 2023

J. B. CHEMICALS & PHARMACEUTICALS LIMITED - marketscreener.com

<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxQWklHZy0wM3ZWX09tNktpSWNOY0xEMUpyTGdPSkktSVNxeV9CYmZtOXpkWGtHMUhhNGY1QThxWXltaktnU0lxZkxUbXh4WVR3LWhqb0Q3RkVfX0tNQl85a2RKSDVHVmtOSUswRkRLSVF0UmtMTl9hbXFrWWxvTjNtZ21zcW1Bc0RXUEd5N3…

JBCHEPHARM — Frequently Asked Questions

What is the current share price of J. B. Chemicals & Pharmaceuticals Limited (JBCHEPHARM)?

As of 2026-07-15 09:52 IST, J. B. Chemicals & Pharmaceuticals Limited (JBCHEPHARM) trades at ₹2,465.10 on NSE. Its 52-week range is ₹1,585.06 to ₹2,487.60.

What is the market capitalisation of JBCHEPHARM?

J. B. Chemicals & Pharmaceuticals Limited (JBCHEPHARM) has a market capitalisation of ₹39,579.33 Cr on NSE.

What is the P/E ratio of JBCHEPHARM?

JBCHEPHARM trades at a trailing price-to-earnings (P/E) ratio of 59.31. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 9.50.

Does JBCHEPHARM pay a dividend?

J. B. Chemicals & Pharmaceuticals Limited (JBCHEPHARM) currently offers a dividend yield of 0.76%.

What is the return on equity (ROE) of JBCHEPHARM?

JBCHEPHARM has a return on equity (ROE) of 17.06%. Its return on capital employed (ROCE) is 21.88%.

Is JBCHEPHARM a good stock to buy?

This page provides a data-driven analysis of J. B. Chemicals & Pharmaceuticals Limited (JBCHEPHARM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space